Lincoln Pharmaceuticals Ltd
Lincoln Pharmaceuticals Ltd (LINCOLN) last reported results for the quarter ended Jun 2026, with sales of ₹177 crore and net profit of ₹36 crore. The stock last traded at ₹575, a market capitalisation of ₹1,152 crore, on a P/E of 12.0. Over the past 52 weeks the stock has ranged between ₹440 and ₹770. Figures are as of 6 Oct 2026 and are not real time.
Lincoln Pharmaceuticals Ltd share price and key metrics
- Current price
- ₹575
- Market cap
- ₹1,152 cr
- Stock P/E
- 12.0
- Book value
- ₹378
- ROE
- 12.3%
- ROCE
- 16.3%
- Dividend yield
- 0.32%
- 52w high / low
- 770/440
Metrics as of 6 Oct 2026. Not real time.
Track Lincoln Pharmaceuticals Ltd
Cruxal reads every Lincoln Pharmaceuticals Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Lincoln Pharmaceuticals Ltd growth and returns
- 10 Years
- 5%
- 5 Years
- 10%
- 3 Years
- 10%
- TTM
- 10%
- 10 Years
- 14%
- 5 Years
- 7%
- 3 Years
- 7%
- TTM
- 12%
- 10 Years
- 9%
- 5 Years
- 7%
- 3 Years
- 3%
- 1 Year
- 7%
- 10 Years
- 16%
- 5 Years
- 15%
- 3 Years
- 14%
- Last Year
- 12%
Lincoln Pharmaceuticals Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹177 cr, up 14.9% from ₹154 cr a year earlier. Net profit was ₹36 cr, up 28.6% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 161 | 147 | 168 | 154 | 163 | 166 | 187 | 177 |
| Expenses | 133 | 123 | 141 | 130 | 138 | 143 | 162 | 150 |
| Operating profit | 28 | 24 | 27 | 24 | 25 | 24 | 25 | 27 |
| OPM % | 18% | 16% | 16% | 15% | 16% | 14% | 13% | 15% |
| Other income | 10 | 9 | -7 | 15 | 7 | 15 | -4 | 24 |
| Interest | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 |
| Profit before tax | 35 | 29 | 16 | 35 | 29 | 35 | 17 | 48 |
| Tax % | 24% | 28% | 29% | 22% | 31% | 18% | 30% | 24% |
| Net profit | 26 | 21 | 12 | 28 | 20 | 29 | 12 | 36 |
| EPS (₹) | 13.15 | 10.37 | 5.78 | 13.82 | 9.98 | 14.28 | 5.81 | 18.09 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Lincoln Pharmaceuticals Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 360 | 361 | 366 | 386 | 424 | 472 | 510 | 581 | 623 | 671 | 694 |
| Operating profit | 47 | 53 | 68 | 66 | 87 | 96 | 90 | 100 | 102 | 98 | 101 |
| OPM % | 13% | 15% | 18% | 17% | 21% | 20% | 18% | 17% | 16% | 15% | 15% |
| Net profit | 28 | 35 | 49 | 51 | 62 | 69 | 73 | 93 | 82 | 88 | 96 |
| EPS (₹) | 14.06 | 17.31 | 24.36 | 25.72 | 31.12 | 34.63 | 36.40 | 46.58 | 41.11 | 43.88 | 48.16 |
TTM is the trailing twelve months to the most recent quarter.
Lincoln Pharmaceuticals Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 |
| Reserves | 172 | 204 | 249 | 293 | 346 | 413 | 482 | 573 | 652 | 738 |
| Borrowings | 64 | 61 | 34 | 5 | 1 | 2 | 2 | 1 | 0 | 4 |
| Other liabilities | 48 | 62 | 63 | 71 | 85 | 99 | 83 | 106 | 125 | 128 |
| Total liabilities | 305 | 347 | 366 | 389 | 452 | 534 | 587 | 700 | 797 | 890 |
| Fixed assets | 103 | 117 | 121 | 123 | 111 | 132 | 151 | 179 | 182 | 191 |
| CWIP | 7 | 0 | 2 | 0 | 2 | 16 | 7 | 3 | 4 | 5 |
| Investments | 10 | 11 | 18 | 34 | 81 | 97 | 91 | 139 | 174 | 209 |
| Other assets | 186 | 219 | 225 | 232 | 259 | 290 | 339 | 379 | 437 | 486 |
| Total assets | 305 | 347 | 366 | 389 | 452 | 534 | 587 | 700 | 797 | 890 |
As reported by the company. Total assets equal total liabilities by construction.
Lincoln Pharmaceuticals Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 25 | 27 | 53 | 75 | 69 | 76 | 39 | 63 | 93 | 106 |
| Cash from investing | -25 | -12 | -18 | -31 | -64 | -78 | -37 | -57 | -79 | -98 |
| Cash from financing | 0 | -11 | -36 | -38 | -6 | -3 | -4 | -5 | -6 | 0 |
| Net cash flow | -0 | 3 | -1 | 7 | -1 | -4 | -2 | 1 | 8 | 8 |
| Free cash flow | 7 | 17 | 38 | 68 | 61 | 31 | 26 | 24 | 74 | 82 |
| CFO / operating profit | 74% | 68% | 104% | 137% | 102% | 104% | 77% | 89% | 117% | 135% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Lincoln Pharmaceuticals Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 19% | 19% | 23% | 22% | 25% | 24% | 22% | 22% | 17% | 16% |
| Debtor days | 92 | 111 | 122 | 96 | 98 | 90 | 98 | 102 | 97 | 88 |
| Inventory days | 63 | 86 | 75 | 95 | 86 | 121 | 106 | 101 | 99 | 94 |
| Days payable | 54 | 82 | 92 | 102 | 105 | 120 | 77 | 95 | 106 | 100 |
| Cash conversion cycle | 100 | 115 | 106 | 88 | 78 | 91 | 126 | 108 | 90 | 82 |
| Working capital days | 69 | 89 | 113 | 126 | 119 | 113 | 121 | 121 | 116 | 239 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Lincoln Pharmaceuticals Ltd shareholding pattern
Promoters held 49.78% at Jun 2026, broadly unchanged since Jun 2025. FIIs 4.60% and DIIs 0.27%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 49.78% | 49.78% | 49.78% | 49.78% | 49.78% | 49.78% | 49.78% | 49.78% |
| FIIs | 5.19% | 5.16% | 5.00% | 5.13% | 4.73% | 4.70% | 5.20% | 4.60% |
| DIIs | 0.00% | 0.00% | 0.00% | 0.01% | 0.01% | 0.01% | 1.08% | 0.27% |
| Public | 45.04% | 45.07% | 45.23% | 45.08% | 45.49% | 45.51% | 43.94% | 45.36% |
| No. of shareholders | 31,330 | 31,848 | 31,867 | 31,784 | 32,370 | 31,026 | 28,303 | 29,396 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Lincoln Pharmaceuticals Ltd corporate filings
- Certificate from RTA for the Quarter ended September 30, 2026 under Regulation 74(5) of SEBI (DP) Regulations, 2018.Company Updatelow impact
- Lincoln Pharmaceuticals Holds AGM with Strong Voting Support; Approves Financials and DividendsAGM/EGMhigh impact
Cruxal's analysis: Lincoln Pharmaceuticals Limited conducted its 32nd AGM on September 30, 2026, via video…
Read the full analysis - Lincoln Pharmaceuticals Ltd. conducts 32nd AGM with no major financial surprises; declares Rs. 1.80 per share dividend for FY 2025-26AGM/EGMlow impact
Cruxal's analysis: Lincoln Pharmaceuticals Ltd. held its 32nd Annual General Meeting on September 30, 2026…
Read the full analysis - Lincoln Pharmaceuticals appoints new Senior General Manager for Quality AssuranceCompany Updatelow impact
Cruxal's analysis: Lincoln Pharmaceuticals Ltd has announced the appointment of Mr. Pradeep Kumar Yadav as…
Read the full analysis - Lincoln Pharmaceuticals Limited announces resignation of Head of Quality AssuranceCompany Updatelow impact
Cruxal's analysis: Lincoln Pharmaceuticals Limited has formally announced the resignation of Mr. Manoj Rai…
Read the full analysis - Intimation of Closure of Trading Window.Insider Trading / SASTlow impact
- Lincoln Pharmaceuticals announces newspaper publication for 32nd Annual General MeetingCompany Updatelow impact
Cruxal's analysis: Lincoln Pharmaceuticals has completed the mandatory newspaper publication regarding the…
Read the full analysis - Lincoln Pharmaceuticals Ltd: Dispatch of physical annual reports to shareholders without registered email addressesCompany Updatelow impact
Cruxal's analysis: Lincoln Pharmaceuticals has initiated the dispatch of physical copies of its Annual…
Read the full analysis - Lincoln Pharmaceuticals submits Annual Report and Notice of 32nd AGM for FY 2025-2026Otherslow impact
Cruxal's analysis: Lincoln Pharmaceuticals has filed its Annual Report and the formal notice for its 32nd…
Read the full analysis - Lincoln Pharmaceuticals Limited Announces 32nd Annual General Meeting and Dividend DeclarationAGM/EGMlow impact
Cruxal's analysis: Lincoln Pharmaceuticals Limited has issued a notice for its 32nd Annual General Meeting…
Read the full analysis - Lincoln Pharmaceuticals Limited announces record date and book closure for 32nd AGM and final dividend of INR 1.80 per shareCorp. Actionlow impact
Cruxal's analysis: Lincoln Pharmaceuticals Limited has scheduled its 32nd Annual General Meeting for…
Read the full analysis - Lincoln Pharmaceuticals Limited announces book closure for 32nd AGM and final dividend of INR 1.80 per shareCorp. Actionlow impact
Cruxal's analysis: Lincoln Pharmaceuticals Limited has scheduled its 32nd Annual General Meeting for…
Read the full analysis - Lincoln Pharmaceuticals schedules 32nd Annual General Meeting for September 30, 2026Company Updatelow impact
Cruxal's analysis: Lincoln Pharmaceuticals has issued a newspaper advertisement confirming that its 32nd…
Read the full analysis - Lincoln Pharmaceuticals Limited reports Q1 FY2027 financial results; newspaper advertisement confirms complianceCompany Updatelow impact
Cruxal's analysis: Lincoln Pharmaceuticals Limited has published the mandatory newspaper advertisement…
Read the full analysis - Lincoln Pharmaceuticals Q1 FY27 Results: Consolidated Net Profit Surges 30.90% YoY to INR 36.23 CroreBoard Meetinghigh impact
Cruxal's analysis: Lincoln Pharmaceuticals Ltd reported strong Q1 FY27 performance with consolidated net…
Read the full analysis - Lincoln Pharmaceuticals Limited schedules Board Meeting for August 13, 2026, to approve Q1 FY27 financial resultsBoard Meetinglow impact
Cruxal's analysis: Lincoln Pharmaceuticals Limited has formally notified the stock exchanges of a Board…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.